BriaCell Expands Phase 3 Cancer Study with New Clinical Sites

BriaCell Therapeutics ( (TSE:BCT) ) just unveiled an update.

BriaCell Therapeutics has announced the expansion of its pivotal Phase 3 clinical study by adding Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven, which collectively contribute 30 satellite locations. This expansion increases the study’s active clinical sites to 58 across 15 states, enhancing patient access to BriaCell’s lead candidate, Bria-IMT™, in combination with an immune checkpoint inhibitor for advanced metastatic breast cancer. The study’s positive interim data could lead to full approval and marketing authorization, reflecting significant clinical interest and addressing urgent unmet needs in metastatic breast cancer treatment.

The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$15.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.

Spark’s Take on TSE:BCT Stock

According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.

BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.

To see Spark’s full report on TSE:BCT stock, click here.

More about BriaCell Therapeutics

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care.

Average Trading Volume: 17,171

Technical Sentiment Signal: Strong Sell

Current Market Cap: C$27.1M

Find detailed analytics on BCT stock on TipRanks’ Stock Analysis page.